Clinical trial
A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients With Fused in Sarcoma Mutations (FUS-ALS)
NCT04768972 is registered in ClinicalTrials.gov with Ionis Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients With Fused in Sarcoma Mutations (FUS-ALS)
- Lead sponsor
- Ionis Pharmaceuticals, Inc.
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- June 14, 2021
- Completion date
- March 31, 2028
- Enrollment
- 89 (actual)
- Sites
- 25
Conditions
As the registry lists them; a condition with its own page is linked.